Kezar Life Sciences, Inc. (KZR) Total Current Liabilities (2017 - 2026)

Kezar Life Sciences has reported Total Current Liabilities for 10 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Total Current Liabilities fell 83.72% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 83.72% YoY) and the FY2025 annual result came in at $6.6 million, down 67.66% from the prior year.
• Total Current Liabilities slipped to $2.8 million in Q1 2026 per KZR's latest filing, from $6.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $20.4 million in Q3 2024 and troughed at $2.8 million in Q1 2026.
• A 5-year average of $13.3 million and a median of $13.7 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities surged 95.53% in 2023, then plunged 83.72% in 2026.
• Over 5 years, Total Current Liabilities stood at $11.0 million in 2022, then jumped by 61.35% to $17.7 million in 2023, then climbed by 14.57% to $20.3 million in 2024, then sank by 67.66% to $6.6 million in 2025, then slumped by 57.99% to $2.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.8 million, $6.6 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.